Therefore, thalassemia and sickle cell anemia patients are considered at high atherogenic risk in view of the perturbation of the Hb/heme/iron metabolism that predisposes these patients to oxidative status alterations (Belcher et al., 1999; Switzer et al., 2006). This evidence concerns the gene GSTM1 and sickle cell disease.